Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a strong second quarter of 2020, with significant increases in both revenue and net income compared to the prior year. Total revenues grew by approximately 24% to $1.95 billion, driven by substantial growth in net product sales for Dupixent and Libtayo, along with increased collaboration revenue from Sanofi. Net income more than quadrupled year-over-year, reaching $897.3 million, or $7.61 per diluted share. This financial performance reflects the robust commercial execution across key products and ongoing advancements in the company's extensive clinical pipeline, including progress on REGN-COV2 for COVID-19. Despite the positive financial results, the company is navigating a complex operating environment due to the COVID-19 pandemic, which has impacted clinical trial enrollment and supply chain operations, though management has stated no material impact on financial statements as of this report. Significant events during the quarter included the end of the Praluent collaboration with Sanofi, with Regeneron now solely responsible for U.S. commercialization. Additionally, Sanofi completed a significant sale of its Regeneron shares, reducing its ownership stake. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.
Financial Highlights
43 data points| Revenue | $1.95B |
| R&D Expenses | $722.00M |
| SG&A Expenses | $348.30M |
| Operating Expenses | $1.30B |
| Operating Income | $656.40M |
| Interest Expense | $9.70M |
| Net Income | $897.30M |
| EPS (Basic) | $8.19 |
| EPS (Diluted) | $7.61 |
| Shares Outstanding (Basic) | 109.60M |
| Shares Outstanding (Diluted) | 117.90M |
Key Highlights
- 1Total revenues increased by 24% to $1.95 billion for the three months ended June 30, 2020, compared to $1.58 billion in the prior year period.
- 2Net income surged by 364% to $897.3 million for the three months ended June 30, 2020, compared to $193.1 million in the prior year period.
- 3Diluted earnings per share (EPS) rose to $7.61 from $1.68 in the comparable prior year period.
- 4Net product sales for Dupixent increased significantly by 70% to $945.0 million for the three months ended June 30, 2020, driven by strong growth in the U.S. market.
- 5Collaboration revenue from Sanofi saw a substantial increase of 255% to $269.1 million, largely due to higher profit sharing from Dupixent and Kevzara, and reimbursement for manufacturing.
- 6The company repurchased approximately $5.4 billion of its common stock during the first six months of 2020, including a $5 billion purchase from Sanofi.
- 7Research and development expenses decreased by approximately 18% to $722.0 million for the three months ended June 30, 2020, reflecting lower spending on certain programs and collaboration reimbursements.